Phase 1 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have volunteered to take part and have signed a consent form
• People aged 18 to 75 years old, of any gender
• People who have been diagnosed (confirmed by tissue testing) with certain types of B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma, primary mediastinal B-cell lymphoma, mantle cell lymphoma (MCL), or other related types, where the disease has come back or stopped responding to previous treatments under specific conditions (confirm with trial site for full details)
• People who have at least one measurable area of disease that is 1.5 cm or larger in its longest measurement
• People whose expected survival is at least 12 weeks
• People whose tumour tissue has tested positive for a protein called CD19
• People with a general health and activity level rated 0 to 2 on a standard scale (confirm with trial site)
• People whose liver, kidney, and heart are functioning well enough to meet specific test result thresholds (confirm with trial site for exact values)
• People who have previously had a stem cell transplant
• People who have finished their most recent cancer treatment (such as chemotherapy, radiotherapy, or immunotherapy) at least 3 weeks before starting this trial
• People who have previously received CAR-T cell therapy but whose disease came back or did not respond, assessed at least 3 months after that therapy
• Women of childbearing age who have a negative pregnancy test and agree to use effective contraception during the trial
• People who have tested negative for COVID-19 on two separate tests

Who may not be able to join:

• People who have had an allergic reaction to any ingredient in the type of cell product used in this trial
• People who have a history of any other type of cancer
• People who have previously experienced moderate to severe graft-versus-host disease (a complication sometimes seen after certain transplants), or who are currently receiving treatment for it
• People who have received gene therapy within the past 3 months
• People who have an active infection currently requiring treatment (other than simple urinary tract infections or bacterial throat infections)
• People with hepatitis B (with certain test result exceptions — confirm with trial site), hepatitis C, syphilis, HIV, or other conditions affecting the immune system
• People whose heart function is rated as Grade III or IV under a standard medical classification system
• People who still have significant side effects from previous cancer treatments that have not yet recovered to an acceptable level (with some exceptions such as tiredness, loss of appetite, or hair loss)
• People with a history of epilepsy or other conditions affecting the brain or central nervous system
• People whose brain scan shows signs that lymphoma has spread to the central nervous system
• People who have previously received or are currently receiving another treatment that targets CD19
• Women who are breastfeeding and are not willing to stop
• People whom the trial doctors consider may face increased risk or whose participation may affect the reliability of the trial results

Important: Always verify eligibility with the trial site directly before applying.